Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway-Reference-Cited by-同舟云学术

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway

Published:2018-03-28 Issue:11 Volume:32 Page:2445-2458
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Busch Leonhard,Mougiakakos Dimitrios,Büttner-Herold Maike,Müller Miriam J.,Volmer Dietrich A.,Bach Christian,Fabri Mario,Bittenbring Jörg T.,Neumann Frank,Boxhammer Rainer,Nolting Jens,Bisht Savita,Böttcher Martin,Jitschin Simon,Hoffmann Markus H.,Balzer Heidi,Beier Fabian,Gezer Deniz,Dudziak Diana,Gelse Kolja,Hennig Friedrich F.,Pallasch Christian P.,Spriewald Bernd,Mackensen Andreas^ORCID,Bruns Heiko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0114-0.pdf

Reference46 articles.

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

2. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–57.

3. van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127:681–95.

4. Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau IW, Einsele H, et al. Phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma. Blood. 2015;126:3035–3035.

5. Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21:2802–10.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology to Practice;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Antiproliferative and immunoregulatory actions of vitamin D derivatives on hematological malignancies;Feldman and Pike's Vitamin D;2024

3. Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib;Nutrients;2023-12-31

4. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas;Journal of Investigative Dermatology;2023-07

5. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis;Frontiers in Endocrinology;2023-04-27